BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• 

  IPO

  After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute

  After spinning out of BridgeBio in May 2024, BBOT had an eye on another round of fundraising in 2025. A SPAC quickly emerged as the best option.

  September 3, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  IPO

  After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?

  Some of the biggest SPACs from the industry’s pandemic-fueled heyday are no longer on the market.

  September 3, 2025

   · 

  10 min read

   · 

  Tristan Manalac
• 

  IPO

  SPACs Line Up To Clear Biotech’s IPO Backlog

  Blank check deals dwindled after a crazy 2021. Now, biotechs are starting to turn to special purpose acquisition companies again as an easy route to the public markets.

  September 3, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Opinion

  Gene Therapy Should Not Be a Luxury

  It can cure deadly diseases, save long-term healthcare costs and transform lives. But the U.S. insurance system still isn’t ready to pay for it.

  September 3, 2025

   · 

  7 min read

   · 

  Dennis Sponer
• 

  Podcast

  CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More

  Health Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee Thursday, ahead of a vaccine advisory committee meeting later in September. Meanwhile, deal-making appetite appears healthy, and the weight loss space continues generating clinical data and other news.

  September 3, 2025

   · 

  1 min read

   · 

  Jef Akst
• 

  Cardiovascular disease

  Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study

  Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.

  September 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cardiovascular disease

  Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study

  Aside from lowering triglyceride levels, Ionis’ olezarsen reduced acute pancreatitis events, an outcome that BMO Capital Markets said could help the asset deliver a “significant first-in-class commercial launch.”

  September 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Data Scientist Fourth Fastest-Growing U.S. Job, Says BLS

  Data scientist employment is expected to grow 33.5% from 2024 to 2034 due in part to a growing demand for data analysis, according to new U.S. Bureau of Labor Statistics findings. Biopharma hotspots were among the top 10 states for employment and pay for this role in 2024.

  September 3, 2025

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Cardiovascular disease

  Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment

  Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.

  September 3, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  CDC

  RFK Jr. Blames US COVID Deaths on Chronic Disease, Announcing CDC Reorganization

  In an opinion piece in the Wall Street Journal, Health Secretary Robert F. Kennedy Jr. said he will roll chronic disease programs into a new Administration for a Healthy America.

  September 3, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky